CCL19阳性淋巴结基质细胞通过原肌球蛋白受体激酶调控炎性关节炎的发生
研究在胶原诱导性关节炎(CIA)小鼠中,于发病前对引流淋巴结(pLN)的CCL19阳性淋巴结基质细胞进行5天时空特异性清除,可阻止疾病发生,局部注射重组CCL19-IgG可模拟该抑制效果;CCL19阳性淋巴结基质细胞在发病前下调原肌球蛋白受体激酶A(TrkA),阻断TrkA可增加T细胞增殖,局部pLN给予TrkA抑制剂及TrkA siRNA则加重关节炎评分。
要点
- 发病前清除pLN的CCL19阳性淋巴结基质细胞可阻止CIA小鼠疾病发生。
- 局部CCL19-IgG处理可模拟清除CCL19阳性淋巴结基质细胞的抑制效果。
- 局部pLN抑制TrkA或给予TrkA siRNA会加重关节炎评分。
核心结论
- CCL19阳性淋巴结基质细胞关键参与炎性关节炎的发生,通过TRK靶向CCL19阳性淋巴结基质细胞可能成为预防关节炎的工具。
研究设计与样本
- 使用Ccl19-Cre × iDTR小鼠在胶原诱导性关节炎(CIA)发病前对引流腘窝淋巴结(pLN)的CCL19阳性淋巴结基质细胞进行为期5天的时空特异性清除。
- 局部足垫注射重组CCL19-免疫球蛋白G(IgG)用于验证清除结果。
- 采用淋巴结基质细胞RNA测序、T细胞共培养实验(使用原肌球蛋白受体激酶(Trk)家族抑制剂)及体内局部pLN小干扰RNA(siRNA)处理以阐明通路。
主要发现
- 时空特异性清除CCL19阳性淋巴结基质细胞可阻止CIA小鼠疾病发生。
- 局部CCL19-IgG处理可模拟上述抑制效果。
- 信使RNA测序分析显示CCL19阳性淋巴结基质细胞在发病前下调原肌球蛋白受体激酶A(TrkA)表达。
- 在淋巴结基质细胞中阻断TrkA导致体外共培养实验中T细胞增殖增加。
- 在类风湿关节炎患者淋巴结基质细胞与T细胞的共培养中,pan-Trk抑制剂larotrectinib观察到类似效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study objective was to assess the role of CCL19+ lymph node stromal cells of the joint-draining popliteal lymph node (pLN) for the development of arthritis. METHODS: CCL19+ lymph node stromal cells were spatiotemporally depleted for five days in the pLN before the onset of collagen-induced arthritis (CIA) using Ccl19-Cre × iDTR mice. In addition, therapeutic treatment with recombinant CCL19-immunoglobulin G (IgG), locally injected in the footpad, was used to confirm the results. RNA sequencing of lymph node stromal cells combined with T cell coculture assays using tropomyosin receptor kinase (Trk) family inhibitors together with in vivo local pLN small interfering RNA (siRNA) treatments were used to elucidate the pathway by which CCL19+ lymph node stromal cells initiate the onset of arthritis. RESULTS: Spatiotemporal depletion of CCL19+ lymph node stromal cells prevented disease onset in CIA mice. These inhibitory effects could be mimicked by local CCL19-IgG treatment. The messenger RNA sequencing analyses showed that CCL19+ lymph node stromal cells down-regulated the expression of the tropomyosin receptor kinase A (TrkA) just before disease onset. Blocking TrkA in lymph node stromal cells led to increased T cell proliferation in in vitro coculture assays. Similar effects were observed with the pan-Trk inhibitor larotrectinib in cocultures of lymph node stromal cells of patients with rheumatoid arthritis and T cells. Finally, local pLN treatment with TrkA inhibitor and TrkA siRNA led to exacerbated arthritis scores. CONCLUSION: CCL19+ lymph node stromal cells are crucially involved in the development of inflammatory arthritis. Therefore, targeting of CCL19+ lymph node stromal cells via TRK could provide a tool to prevent arthritis.
引用
- Schälter F, Azizov V, Frech M, et al. CCL19-Positive Lymph Node Stromal Cells Govern the Onset of Inflammatory Arthritis via Tropomyosin Receptor Kinase. Arthritis Rheumatol. 2024. PMID: 38268500. doi:10.1002/art.42807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。